Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
Sponsor: University of Alberta
Summary
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
Official title: The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-06-05
Completion Date
2026-12-31
Last Updated
2026-04-09
Healthy Volunteers
No
Interventions
Placebo
Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
Treprostinil Inhalation Solution 36 mcg
Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Treprostinil Inhalation Solution 78 mcg
Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Locations (1)
Clinical Physiology Laboratory
Edmonton, Alberta, Canada